PTC Therapeutics reported a significant financial turnaround for the nine months ended September 30, 2025, achieving Net Income of $817.6 Million (vs. a \(297.4M loss in 2024) and generating **\)745.5M** in operating cash flow. Total YTD Revenue hit $1.57 Billion, primarily driven by recognizing the $1.0 Billion upfront payment from the January 2025 Novartis votoplam HD collaboration agreement.
Despite the strong overall profitability bolstered by licensing proceeds, Net Product Revenue declined 3% in Q3. Declines were attributed to Translarna following the European Commissi
...